Charles Schwab Investment Management Inc. Grows Stock Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Charles Schwab Investment Management Inc. increased its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 1.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 328,034 shares of the company’s stock after buying an additional 5,438 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.68% of Axsome Therapeutics worth $27,755,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of AXSM. R Squared Ltd purchased a new stake in shares of Axsome Therapeutics in the 4th quarter worth approximately $64,000. KBC Group NV grew its holdings in Axsome Therapeutics by 40.5% in the fourth quarter. KBC Group NV now owns 1,336 shares of the company’s stock worth $113,000 after purchasing an additional 385 shares during the last quarter. Moors & Cabot Inc. acquired a new position in Axsome Therapeutics during the 3rd quarter valued at approximately $200,000. Whalen Wealth Management Inc. acquired a new position in Axsome Therapeutics during the 3rd quarter valued at approximately $236,000. Finally, Flower City Capital acquired a new position in Axsome Therapeutics during the 4th quarter valued at approximately $254,000. 81.49% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Axsome Therapeutics

In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of Axsome Therapeutics stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $131.07, for a total transaction of $393,210.00. Following the sale, the chief financial officer now directly owns 42,187 shares of the company’s stock, valued at approximately $5,529,450.09. The trade was a 6.64 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 22.40% of the stock is currently owned by company insiders.

Axsome Therapeutics Stock Performance

AXSM stock opened at $125.68 on Tuesday. The firm has a market cap of $6.13 billion, a PE ratio of -20.98 and a beta of 1.00. The company has a quick ratio of 2.04, a current ratio of 2.11 and a debt-to-equity ratio of 3.22. Axsome Therapeutics, Inc. has a 12-month low of $64.11 and a 12-month high of $139.13. The business has a 50 day moving average of $113.06 and a 200-day moving average of $99.22.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.01. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%. The company had revenue of $118.77 million during the quarter, compared to the consensus estimate of $117.83 million. As a group, sell-side analysts expect that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on AXSM. Cantor Fitzgerald reissued an “overweight” rating and set a $153.00 price target on shares of Axsome Therapeutics in a report on Wednesday, February 19th. Mizuho lifted their price target on shares of Axsome Therapeutics from $195.00 to $212.00 and gave the company an “outperform” rating in a research report on Wednesday, February 26th. HC Wainwright reaffirmed a “buy” rating and set a $200.00 price objective on shares of Axsome Therapeutics in a research report on Thursday, March 6th. Deutsche Bank Aktiengesellschaft began coverage on Axsome Therapeutics in a research report on Tuesday, February 11th. They set a “buy” rating and a $176.00 price objective for the company. Finally, Bank of America boosted their price objective on Axsome Therapeutics from $143.00 to $167.00 and gave the company a “buy” rating in a research note on Tuesday, February 11th. One research analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat, Axsome Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $167.36.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.